Answers are grounded in this paper and cite their sources.
Introduction: FLT3 mutations are identified in 20–30% of acute myeloid leukemia (AML) and are associated with a poor prognosis due to chemotherapy refractory disease and short relapse-free survival. Numerous FLT3 tyrosine kinase inhibitors have been evaluated. The first FLT3 inhibitor approved for therapy of FLT3 mutant relapsed/refractory AML (RR-AML) is gilteritinib.Areas covered: We discuss how gilteritinib represents the next generation of FLT3 tyrosine kinase inhibitors with highly potent and specific activity against FLT3 activating mutations (ITD and TKD) found in AML. We review how gilteritinib differs from prior FLT3 inhibitors, which exhibited broad-spectrum kinase activity but poor in vivo pharmacokinetics, off-target toxicities, and no clinically meaningful single agent responses. We discuss clinical trial results demonstrating the safety and improved clinical activity of gilteritinib over standard chemotherapy in FLT3 mutant RR-AML patients. Lastly, we discuss ongoing trials of gilteritinib with chemotherapy and other targeted approaches.Expert opinion: Gilteritinib represents the next generation of FLT3 inhibitors for AML therapy. Upfront regimens incorporating this agent are likely to become the new standard of care for FLT3 mutant de novo AML, and newer combinations hold promise to further transform the therapeutic landscape for this AML subset in the near future.
No takes yet. Share an insight, caveat, or question.
Eunice S. Wang (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: